Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 10;13(8):2176.
doi: 10.3390/jcm13082176.

Diagnosis, Treatment and Long-Term Management of Vitamin B12 Deficiency in Adults: A Delphi Expert Consensus

Affiliations

Diagnosis, Treatment and Long-Term Management of Vitamin B12 Deficiency in Adults: A Delphi Expert Consensus

Rima Obeid et al. J Clin Med. .

Abstract

Background/Objectives: Vitamin B12 deficiency can cause variable symptoms, which may be irreversible if not diagnosed and treated in a timely manner. We aimed to develop a widely accepted expert consensus to guide the practice of diagnosing and treating B12 deficiency. Methods: We conducted a scoping review of the literature published in PubMed since January 2003. Data were used to design a two-round Delphi survey to study the level of consensus among 42 experts. Results: The panelists agreed on the need for educational and organizational changes in the current medical practices for diagnosing and treating B12 deficiency. Recognition of clinical symptoms should receive the highest priority in establishing the diagnosis. There is agreement that the serum B12 concentration is useful as a screening marker and methylmalonic acid or homocysteine can support the diagnosis. Patient lifestyle, disease history, and medications can provide clues to the cause of B12 deficiency. Regardless of the cause of the deficiency, initial treatment with parenteral B12 was regarded as the first choice for patients with acute and severe manifestations of B12 deficiency. The use of high-dose oral B12 at different frequencies may be considered for long-term treatment. Prophylactic B12 supplementation should be considered for specific high-risk groups. Conclusions: There is a consensus that clinical symptoms need to receive more attention in establishing the diagnosis of B12 deficiency. B12 laboratory markers can support the diagnosis. The severity of clinical symptoms, the causes of B12 deficiency, and the treatment goals govern decisions regarding the route and dose of B12 therapy.

Keywords: anemia; cognitive decline; diagnosis; neuropathy; treatment; vitamin B12 deficiency.

PubMed Disclaimer

Conflict of interest statement

All authors received consulting fees and travel costs from Wörwag Pharma in relation to their role in this study. JS lectured and consulted for TEVA, AbbVie, Ipsen, Roche, Novartis, Biogen, Novo Nordisk, Sanofi, Takeda, and Amicus. RC received institutional grants from Amgen, Amryt Pharma, Novartis, and Sanofi and received honoraria for consulting and lectures from Amgen, Amryt Pharma, Astra Zeneca, Bayer, Boehringer Ingelheim, ExCEEd Orphan, Sanofi, Zentiva, AOP Orphan, Bayer, Roche, and Servier. AE received support for attending meetings from Amgen and received a consulting honorary from BMS, Pfizer, and Boehringer Ingelheim. The authors declare that Wörwag Pharma paid for study materials, scientific editing, and article processing charges.

Figures

Figure 1
Figure 1
Symptoms of B12 deficiency ordered from the most to the least difficult for being linked to B12 deficiency. Although neuropsychiatric symptoms are more frequent than hematological abnormalities, they are less specific, more demanding to recognize, and thus more difficult to link to B12 deficiency.
Figure 2
Figure 2
Diagnostic algorithm for vitamin B12 deficiency assessment. The vitamin B12 deficiency diagnostic algorithm was based on a consensus of 42 panelists [mean (95% confidence intervals of the agreement level) = 0.76 (0.61 − 0.88)]. * Full blood cell count and serum B12 concentration; § Serum concentrations of holotranscobalamin, methylmalonic acid, total homocysteine, gastrin, antibodies against parietal cells and/or intrinsic factor and specific tests of the respective specialties. Special diagnostic tests are subject to availability.

Similar articles

Cited by

References

    1. Healton E.B., Savage D.G., Brust J.C., Garrett T.J., Lindenbaum J. Neurologic aspects of cobalamin deficiency. Medicine. 1991;70:229–245. doi: 10.1097/00005792-199107000-00001. - DOI - PubMed
    1. Miceli E., Lenti M.V., Padula D., Luinetti O., Vattiato C., Monti C.M., Di Stefano M., Corazza G.R. Common features of patients with autoimmune atrophic gastritis. Clin. Gastroenterol. Hepatol. 2012;10:812–814. doi: 10.1016/j.cgh.2012.02.018. - DOI - PubMed
    1. Misra U.K., Kalita J. Comparison of clinical and electrodiagnostic features in B12 deficiency neurological syndromes with and without antiparietal cell antibodies. Postgrad. Med. J. 2007;83:124–127. doi: 10.1136/pgmj.2006.048132. - DOI - PMC - PubMed
    1. Divate P.G., Patanwala R. Neurological manifestations of B(12) deficiency with emphasis on its aetiology. J. Assoc. Physicians India. 2014;62:400–405. - PubMed
    1. Aaron S., Kumar S., Vijayan J., Jacob J., Alexander M., Gnanamuthu C. Clinical and laboratory features and response to treatment in patients presenting with vitamin B12 deficiency-related neurological syndromes. Neurol. India. 2005;53:55–58. - PubMed

LinkOut - more resources